DEC 2014 ARTICLE LIST >>
PharmaTutor (December- 2014)
ISSN: 2347 - 7881
(Volume 2, Issue 12)
Received On: 22/10/2014; Accepted On: 28/10/2014; Published On: 01/12/2014
AUTHORS: Monjur Ahmed Laskar*, Manabendra Dutta Choudhury
Bioinformatics Centre, Assam University,
Silchar, Assam, India
monjur@bioinfoaus.ac.in
ABSTRACT: Plants have been used in treating cardiovascular diseases (CVD) and are recognized for their ability to produce secondary metabolites. Secondary metabolites obtained from different plants have been the starting material for designing different drugs. Echinosystic acid, a pentacyclic triterpene was isolated and identified from the fruits of Gleditsia sinensis Lam. Echinosystic acid has significant cardioprotective effects. Different phytochemicals have been found to be cardioprotective and paved the path towards development of cardioprotective formulations. In the present study we have analyzed the inhibitory potential of Echinosystic acid, on the Angiotensin Converting Enzyme (ACE) - the enzyme responsible for various cardiovascular diseases.
The study revealed that Echinosystic acidhave high ACE inhibiting potential as compared to other known ACE inhibitors.
How to cite this article: MA Laskar, MD Choudhury; Angiotensin Converting Enzyme inhibitory potential of Echinosystic acid relevance to Cardiovascular diseases: An in silico study; PharmaTutor; 2014; 2(12); 107-113
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1. Finegold J.A., Asaria P., Francis D.P; Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. Int J Cardiol 2013; 168(2):934-45.
2. Shi L., Mao C., Xu Z., Zhang L; Angiotensin Converting Enzyme and drug discovery in cardiovascular diseases. Drug Discovery Today 2010; 15:332-341.
3. Sridevi P., Prashanth K.S., Bhagavan M.R; Angiotensin Converting Enzyme: A Target for Anti-Hypertensive Drugs. Int J Res Pharm Biomed Sc 2011; 2:63-72.
4. Morrell N.W., Atochina E.N., Morris K.G., Danilov S.M., Stenmark K.R; Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. J Clin Invest 1995; 96 (4):1823-33.
5. Healey J.S., Baranchuk A., Crystal E., Morillo C.A., Garfinkl M., Yusuf S., Connolly S.J; Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. J Am Coll Cardiol 2005; 45:1832–9.
6. Peng H., Carretero O.A., Vuljaj N., Liao T.D., Motivala A., Peterson E.L, Rhaleb N.E; Angiotensin-Converting Enzyme Inhibitors: A New Mechanism of Action. J Am Heart Assoc 2005; 112:2436-2445.
7. Khalil M.E., Basher A.W., Brown E.J., Alhaddad I.A; A Remarkable Medical Story: Benefits of Angiotensin-Converting Enzyme Inhibitors in Cardiac Patients. J Am Coll Cardiol 2001; 37(7): 1757-1764.
8. O’Keefe J.H., Wetzel M., Moe R.R., Brosnahan K., Lavie C.J; Should an Angiotensin Converting Enzyme Inhibitor Be Standard Therapy for Patients With Atherosclerotic Disease? J Am Coll Cardiol 2001; 37:1–8.
9. Wu J., Li J., Zhu Z., Li J., Huang G., Tang Y., Gao X; Protective effects of echinocystic acid isolated from Gleditsia sinensis Lam. against acute myocardial ischemia. Fitoterapia; 2010; 81: 8–10.
10. Laskar M.A., Choudhury M.D., Chetia P; In silico screening of cardioprotective activity of some flavonols. International Journal of Pharmacy and Pharmaceutical Sciences; 2014; 6(2):528-531.
11. O'Boyle N.M., Banck M., James C.A., Morley C., Vandermeersch T., Hutchison G.R; Open Babel: An open chemical toolbox, J Chem Inf 2011; 3:33.
12. Brown N.J., Vaughan D.E; Angiotensin-Converting Enzyme Inhibitors. J Am Heart Assoc 1998; 97:1411-1420.
13. Yu H., Adedoyin A; ADME–Tox in drug discovery: integration of experimental and computational technologies. Drug Discovery Today 2003; 8 : 852–861.
14. Neron B., Menager H., Maufrais C., Joly N., Maupetit J., Letort S., Carrere S., Tuffery P., Letondal C; Mobyle: a new full web bioinformatics framework. 2009; 25: 3005-3011.
15. Laurie A.T., Jackson R.M; Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites. Bioinformatics 2005;21: 1908-1916.
16. Krovat E.M., Steindl T., Langer T; Recent advances in docking and scoring. Curr. Comp. Aided Drug Design 2005; 1: 93-102.
17. Sherborne B.S., Wilkinson T., Bennett J., Borkakoti N., Broadhurst M., Hurst D., Kilford I., McKinnell M., Jones P.S; Discovery of novel low molecular weight inhibitors of IMPDH via virtual needle screening. Bioorg Med Chem Lett 2003;13:1691-1694.
18. Forino M., Jung D., Easton J.B., Houghton P.J., Pellecchia M; Virtual Docking Approaches to Protein Kinase B Inhibition. J. Med. Chem 2005; 48: 2278-2281.
19. Bikadi Z., Demko L., Hazai E; Functional and structural characterization of a protein based on analysis of its hydrogen bonding network by hydrogen bonding plot. Arch Biochem Biophys 2007; 461:225-234.
20. Riordan J.F; Angiotensin-I-converting enzyme and its relatives, Genome Biology 2003; 4:225.1-225.5.
.png)
